(Pamrevlumab)Biosimilar Reference Antibody-GS40528 新品

货号：GS40528

Pamrevlumab (also known as FG‑3019) is a fully human monoclonal antibody that targets connective tissue growth factor (CTGF, also known as CCN2), a matricellular protein involved in tissue remodeling, fibrosis, and tumor progression. By binding to CTGF, pamrevlumab inhibits its interaction with extracellular matrix components and cell‑surface receptors (e.g., integrins), thereby disrupting CTGF‑mediated signaling pathways that drive fibrosis, inflammation, and cancer‑associated stromal desmoplasia. It has been investigated as an anti‑fibrotic and anti‑tumor agent for the treatment of idiopathic pulmonary fibrosis (IPF), pancreatic ductal adenocarcinoma (PDAC), and Duchenne muscular dystrophy (DMD).